BioSpace News Archive

Study drug dosing regimen to increase to 5 days (from 3 days) based on DMC recommendation Enrollment has reached 25 percent in the Company’s ~120-patient Phase 2 COVID-19 clinical trial

MindMed (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ), a leading clinical-stage psychedelic medicine biotech company, announced the publication of the first study on MDMA dosing optimization using personalized medicine.

Invitae (NYSE: NVTA), a leading medical genetics company, today announced that a small group of investors, led by SB Management, a subsidiary of Softbank Group Corp., will make an investment of $1.15 billion in convertible senior notes to support the Company’s future growth initiatives.

Announcing a think tank-style meeting designed to develop actionable plans for schools to reopen and stay open [05-April-2021] BOSTON , April 5, 2021 /PRNewswire/ -- The Virus Project announced today that Meenta and their online marketplace for clinical testing, will be supporting the Back to Schools Conference April 12-14 th in Las Vegas that will bring to

RenalytixAI plc (LSE: RENX) (NASDAQ: RNLX), announced today that KidneyIntelX™ more accurately predicted progressive kidney function decline and kidney failure in a multi-center, diverse cohort of 1,146 type 2 diabetes patients with early-stage (stages 1, 2, and 3) kidney disease versus the current standard of care.

Myovant Sciences, a healthcare company focused on redefining care for women and for men, announced the appointment of Lauren Merendino as Chief Commercial Officer of Myovant Sciences, Inc., effective April 5, 2021.

Clearside Biomedical, Inc., a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced that Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer, will present at two upcoming virtual conferences in April 2021:.

Passage Bio, Inc., a clinical-stage genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system disorders, announced that the European Commission has granted Orphan designation for PBKR03, an adeno-associated virus -delivery gene therapy for the treatment of Krabbe disease.

Conference to include interim results from the open-label extension of the PULSAR Phase 2 trial showing consistent or improved responses in efficacy endpoints among sotatercept-treated patients

Affygility Solutions, an occupational health and safety consulting firm for the life sciences industry, announced its expansion into Brazil.